Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. (3rd July 2016)

• Record Type: Journal Article
• Authors: Ripamonti, Diego; Tatarelli, Paola; Mangili, Giovanna; Gotta, Cristina; Benatti, Simone V.; Bruzzone, Bianca; Callegaro, Anna; Viscoli, Claudio; Ruggeri, Maurizio; Biagio, Antonio Di
• Is Part Of: Journal of chemotherapy. Volume 28:Number 4(2016:Aug.)
• Page Start: 337
• Page End: 340
• Publication Date: 2016-07-03
• Subjects: Raltegravir -- Infants -- Antiretroviral -- HIV-infected children -- HAART; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947814Y.0000000217
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : We report safety and tolerability of raltegravir (RAL) as a forth HIV agent in two highly viraemic newborns. Raltegravir (6 mg/kg) was given orally twice daily. The other antiretrovirals were assumed according to standard dose for newborns. The first baby was born at week 36. An antiretroviral therapy consisting of zidovudine, lamivudine, and lopinavir/ritonavir was started 96 hour after delivery. Raltegravir was added at hour 120, being plasma HIV-1 RNA above 10×10 6 copies/ml. HIV RNA declined to 5·000 copies/ml at day 30. The second baby was born at week 40. He was started on zidovudine, lamivudine, and nevirapine at day 0, while RAL was added at day 3. Plasma HIV-1 RNA declined from 6·6×10 6 at birth to 52 copies/ml at day 28. RAL tolerability was good in both patients, one with gamma-glutamyltransferase increase, which normalized after RAL discontinuation. Raltegravir-based four drug regimen may be effective and well tolerated in highly viraemic HIV neonates up to 4 weeks.